JP2015521050A5 - - Google Patents

Download PDF

Info

Publication number
JP2015521050A5
JP2015521050A5 JP2015515598A JP2015515598A JP2015521050A5 JP 2015521050 A5 JP2015521050 A5 JP 2015521050A5 JP 2015515598 A JP2015515598 A JP 2015515598A JP 2015515598 A JP2015515598 A JP 2015515598A JP 2015521050 A5 JP2015521050 A5 JP 2015521050A5
Authority
JP
Japan
Prior art keywords
maf
subject
expression level
copy number
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015515598A
Other languages
English (en)
Japanese (ja)
Other versions
JP6386450B2 (ja
JP2015521050A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2013/001859 external-priority patent/WO2013182912A2/en
Publication of JP2015521050A publication Critical patent/JP2015521050A/ja
Publication of JP2015521050A5 publication Critical patent/JP2015521050A5/ja
Application granted granted Critical
Publication of JP6386450B2 publication Critical patent/JP6386450B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015515598A 2012-06-06 2013-06-06 肺がん転移の診断、予後診断および処置のための方法 Active JP6386450B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261656372P 2012-06-06 2012-06-06
US61/656,372 2012-06-06
PCT/IB2013/001859 WO2013182912A2 (en) 2012-06-06 2013-06-06 Method for the diagnosis, prognosis and treatment of lung cancer metastasis

Publications (3)

Publication Number Publication Date
JP2015521050A JP2015521050A (ja) 2015-07-27
JP2015521050A5 true JP2015521050A5 (https=) 2016-08-04
JP6386450B2 JP6386450B2 (ja) 2018-09-05

Family

ID=49237517

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015515598A Active JP6386450B2 (ja) 2012-06-06 2013-06-06 肺がん転移の診断、予後診断および処置のための方法

Country Status (13)

Country Link
US (2) US10006091B2 (https=)
EP (2) EP3467124A1 (https=)
JP (1) JP6386450B2 (https=)
KR (1) KR102226219B1 (https=)
CN (1) CN104603288B (https=)
AU (2) AU2013273242B2 (https=)
BR (1) BR112014030750A2 (https=)
CA (1) CA2875918A1 (https=)
DK (1) DK2859120T3 (https=)
ES (1) ES2705237T3 (https=)
MX (1) MX368513B (https=)
TR (1) TR201819859T4 (https=)
WO (1) WO2013182912A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108192972B (zh) 2010-10-06 2022-09-09 生物医学研究机构基金会 用于乳腺癌转移的诊断、预后和治疗的方法
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
BR112014030750A2 (pt) 2012-06-06 2017-08-22 Inst Catalana Recerca Estudis Avancats Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar
ES2906586T3 (es) * 2012-10-12 2022-04-19 Inbiomotion Sl Método para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
CA2906394A1 (en) * 2013-03-15 2014-09-18 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
WO2014184679A2 (en) * 2013-03-15 2014-11-20 Inbiomotion S.L. Method for the prognosis and treatment of renal cell carcinoma metastasis
US20160040247A1 (en) 2013-03-15 2016-02-11 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Method for the diagnosis, prognosis, and tratment of cancer metastasis
EP3149210B1 (en) 2014-06-02 2020-08-05 Valley Health System Method for lung cancer diagnosis
CN104398506A (zh) * 2014-12-09 2015-03-11 厦门大学 雷奈酸锶在制备预防和治疗腺癌药物中的新用途
KR20170093182A (ko) * 2014-12-11 2017-08-14 인바이오모션 에스.엘. 인간 c-maf에 대한 결합 구성원
RU2017135072A (ru) 2015-03-12 2019-04-10 Мори Матрикс, Инк. Применение пептидсодержащих композиций ингибитора mk2 для лечения немелкоклеточного рака легкого
AU2016278040B2 (en) 2015-06-16 2019-07-04 Nanophagix LLC Drug delivery and imaging chemical conjugate, formulations and methods of use thereof
CN105154542B (zh) * 2015-09-01 2018-04-17 杭州源清生物科技有限公司 一组用于肺癌分子分型的基因及其应用
KR20190003938A (ko) 2016-02-25 2019-01-10 셀 메디카 스위처란트 아게 면역치료를 위한 변형된 세포
MY194948A (en) * 2016-05-13 2022-12-28 Golden Biotechnology Corp Methods and compositions for treating advanced stage non-small cell lung cancer
WO2017201043A1 (en) * 2016-05-16 2017-11-23 Concert Pharmaceuticals, Inc. Combination therapy for treating cancer
US11596642B2 (en) 2016-05-25 2023-03-07 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-MAF status
CN106055921A (zh) * 2016-05-27 2016-10-26 华中农业大学 基于基因表达和药物靶标的药物活性预测与筛选方法
CN106119405B (zh) * 2016-08-31 2019-11-12 广州万德基因医学科技有限公司 一种肺癌的预后标记物、使用该标记预测肺癌预后的方法及应用
CN107058480B (zh) * 2016-12-14 2018-07-13 河北医科大学第四医院（河北省肿瘤医院） 用于诊断肺腺癌的长链非编码rna标志物
CN106815486B (zh) * 2017-01-22 2021-06-04 华中农业大学 一种个性化用药的系统药理学方法
CN107058499B (zh) * 2017-01-25 2020-03-13 河北医科大学第四医院（河北省肿瘤医院） 一种用于肺腺癌诊治的分子标志物
KR20200104298A (ko) 2017-11-22 2020-09-03 인바이오모션 에스.엘. c-MAF 상태에 기반한 유방암의 요법 치료
WO2019152788A1 (en) * 2018-02-02 2019-08-08 Morgan And Mendel Genomics, Inc. Robust genomic predictor of breast and lung cancer metastasis
KR102218199B1 (ko) 2019-01-31 2021-02-22 중앙대학교 산학협력단 폐암 전이 예측용 바이오마커 조성물
CN110157792A (zh) * 2019-04-22 2019-08-23 中山大学孙逸仙纪念医院 血清外泌体has_circ_0004771在制备酒精依赖综合征诊断试剂中的应用
CN110093422A (zh) * 2019-05-24 2019-08-06 中国人民解放军西部战区总医院 Linc02159在肺腺癌诊疗中的应用
KR102260915B1 (ko) * 2020-02-19 2021-06-04 한국원자력의학원 폐암의 방사선 치료 예후 예측을 위한 생체 표지자
CN119143798B (zh) * 2024-08-01 2025-09-30 河北医科大学 一种骨靶向阿仑膦酸-普萘洛尔及其制备方法与应用
CN119876392B (zh) * 2025-01-06 2025-08-12 上海市第六人民医院 一种用于辅助诊断肺腺癌骨转移的生物标志物

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE89314T1 (de) 1985-02-13 1993-05-15 Scios Nova Inc Menschlicher metallothionein ii-promotor in saeugetierexpressionssystemen.
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
AU734051B2 (en) 1996-04-05 2001-05-31 Salk Institute For Biological Studies, The Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto
US6242213B1 (en) 1996-12-23 2001-06-05 Immunex Corporation Isolated DNA molecules encoding RANK-L
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US6274338B1 (en) 1998-02-24 2001-08-14 President And Fellows Of Harvard College Human c-Maf compositions and methods of use thereof
CN1362947A (zh) 1999-03-15 2002-08-07 Axys药物公司 用作蛋白酶抑制剂的n－氰基甲基酰胺
TW404030B (en) 1999-04-12 2000-09-01 Siliconware Precision Industries Co Ltd Dual-chip semiconductor package device having malposition and the manufacture method thereof
US6287813B1 (en) 1999-04-23 2001-09-11 Cistronics Cell Technology Gmbh Antibiotic-based gene regulation system
WO2001049288A1 (en) 2000-01-06 2001-07-12 Merck Frosst Canada & Co. Novel compounds and compositions as protease inhibitors
EP1356093A2 (en) * 2000-06-21 2003-10-29 Hitachi Chemical Co., Ltd. Gene markers for lung cancer
US6750015B2 (en) 2000-06-28 2004-06-15 Kathryn B. Horwitz Progesterone receptor-regulated gene expression and methods related thereto
PH12012502440A1 (en) 2001-06-26 2013-06-17 Amgen Inc Antibodies to opgl
AR036375A1 (es) 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
KR100485271B1 (ko) 2002-01-16 2005-04-27 메타볼랩(주) 전사인자 ｃ－ｍａｆ의 전사 활성 억제제로서의 니발레놀및 그를 포함하는 약제학적 조성물
SE0201980D0 (sv) 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
DE10235624A1 (de) 2002-08-02 2004-02-19 Aventis Pharma Deutschland Gmbh Endiandric acid H und ihre Derivate, Verfahren zu ihrer Herstellung und Verwendung derselben
US20050060771A1 (en) 2003-09-11 2005-03-17 Farmer Andrew Alan siRNA encoding constructs and methods for using the same
AU2003286499A1 (en) 2003-10-17 2004-06-06 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Interference with c-maf function in multiple myeloma
US20090048117A1 (en) 2003-12-18 2009-02-19 President And Fellows Of Harvard College Modulation of immune system function by modulation of polypeptide arginine methyltransferases
TW200526224A (en) 2003-12-22 2005-08-16 Alcon Inc Short form c-Maf transcription factor antagonists for treatment of glaucoma
US8019552B2 (en) * 2004-03-05 2011-09-13 The Netherlands Cancer Institute Classification of breast cancer patients using a combination of clinical criteria and informative genesets
WO2006012221A2 (en) 2004-06-25 2006-02-02 The Regents Of The University Of California Target cell-specific short interfering rna and methods of use thereof
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
US9134237B2 (en) 2005-09-20 2015-09-15 Janssen Diagnotics, LLC High sensitivity multiparameter method for rare event analysis in a biological sample
ES2886923T3 (es) 2005-09-20 2021-12-21 Menarini Silicon Biosystems Spa Métodos y composición para generar sondas de ADN de secuencia única, marcaje de sondas de ADN y el uso de estas sondas
EP1931994A2 (en) 2005-09-26 2008-06-18 Novartis AG Molecular markers associated with bone metastasis
EP1969000A2 (en) 2005-12-06 2008-09-17 Centre National de la Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
WO2008098351A1 (en) 2007-02-14 2008-08-21 University Health Network Treatment of d-cyclin mediated proliferative diseases and hemotological malignancies
EP1961825A1 (en) * 2007-02-26 2008-08-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Method for predicting the occurrence of metastasis in breast cancer patients
US20100215588A1 (en) * 2007-04-26 2010-08-26 Rami Skaliter Therapeutic delivery of inhibitory nucleic acid molecules to the respiratory system
CN101796072B (zh) 2007-05-24 2014-09-24 埃博灵克斯股份有限公司 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽
US20110123617A1 (en) 2007-10-18 2011-05-26 University Health Network Clioquinol for the treatment of hematological malignancies
CA2726537A1 (en) 2008-06-06 2009-12-10 University Health Network 8-hydroxyquinoline derivatives for the treatment of hematological malignancies
CA2729521A1 (en) * 2008-07-02 2010-01-07 Assistance Publique Hopitaux De Paris A method for predicting clinical outcome of patients with non-small cell lung carcinoma
CN108192972B (zh) 2010-10-06 2022-09-09 生物医学研究机构基金会 用于乳腺癌转移的诊断、预后和治疗的方法
CA2826657A1 (en) 2011-02-04 2012-08-09 Bioarray Therapeutics, Inc. Methods of using gene expression signatures to select a method of treatment, predict prognosis, survival, and/or predict response to treatment
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
BR112014030750A2 (pt) 2012-06-06 2017-08-22 Inst Catalana Recerca Estudis Avancats Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
ES2906586T3 (es) 2012-10-12 2022-04-19 Inbiomotion Sl Método para el diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata
US20160040247A1 (en) 2013-03-15 2016-02-11 Fundació Institut De Recerca Biomèdica (Irb Barcelona) Method for the diagnosis, prognosis, and tratment of cancer metastasis
WO2014184679A2 (en) 2013-03-15 2014-11-20 Inbiomotion S.L. Method for the prognosis and treatment of renal cell carcinoma metastasis
CA2906394A1 (en) * 2013-03-15 2014-09-18 Fundacio Institut De Recerca Biomedica (Irb Barcelona) Method for the prognosis and treatment of cancer metastasis
DK3055429T3 (en) 2013-10-09 2019-04-23 Fundacio Inst De Recerca Biomedica Irb Barcelona Procedure for the prognosis and treatment of metastatic bone cancer resulting from breast cancer
CN107073040A (zh) 2014-06-17 2017-08-18 艾基诺米公司 子宫内膜病理状况中的干细胞治疗
KR20170093182A (ko) 2014-12-11 2017-08-14 인바이오모션 에스.엘. 인간 c-maf에 대한 결합 구성원
US11596642B2 (en) 2016-05-25 2023-03-07 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-MAF status
KR20200104298A (ko) 2017-11-22 2020-09-03 인바이오모션 에스.엘. c-MAF 상태에 기반한 유방암의 요법 치료

Similar Documents

Publication Publication Date Title
JP2015521050A5 (https=)
Meng et al. Diagnostic and prognostic potential of serum miR-7, miR-16, miR-25, miR-93, miR-182, miR-376a and miR-429 in ovarian cancer patients
JP2016516403A5 (https=)
Thomas et al. Expression profiling of cervical cancers in I ndian women at different stages to identify gene signatures during progression of the disease
JP2015520606A5 (https=)
WO2013182912A4 (en) Method for the diagnosis, prognosis and treatment of lung cancer metastasis
Shames et al. High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck
JP2016539625A5 (https=)
JP2016105731A5 (https=)
JP5690588B2 (ja) 肝細胞癌のサブタイプを決定し、肝癌幹細胞を検出するための方法
Al-Khanbashi et al. Tissue and serum miRNA profile in locally advanced breast cancer (LABC) in response to neo-adjuvant chemotherapy (NAC) treatment
Cui et al. LncRNA FAM230B promotes gastric cancer growth and metastasis by regulating the miR-27a-5p/TOP2A axis
Hung et al. Up-regulation of microRNA-190b plays a role for decreased IGF-1 that induces insulin resistance in human hepatocellular carcinoma
JP2013541339A5 (https=)
JP2018078911A5 (https=)
ES2748005T3 (es) Método para predecir la respuesta a agentes terapéuticos de cáncer de mama y método de tratamiento de cáncer de mama
JP2010535473A5 (https=)
JP2012522756A5 (https=)
Davidson et al. Gene expression signatures differentiate adenocarcinoma of lung and breast origin in effusions
JP6931926B2 (ja) 遺伝子発現プロファイル及び乳癌におけるその使用
JP2014533960A5 (https=)
Pan et al. miR-566 functions as an oncogene and a potential biomarker for prognosis in renal cell carcinoma
WO2010101916A1 (en) Methods for predicting cancer response to egfr inhibitors
Puente et al. Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma
Davidson Biomarkers of drug resistance in ovarian cancer–an update